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Chimpanzee immunoglobulins are virtually identical to human immunoglobulins and may have clinically useful applications.
Four chimpanzee monoclonal antibodies (MAbs) to the hepatitis A virus (HAV) capsid were isolated from a combinatorial
cDNA library of g1/k antibody genes using phage display. Competition assays indicated that three of the MAbs recognized
the same or overlapping epitopes, whereas the fourth recognized a different, nonoverlapping epitope on the HAV capsid. All
four MAbs neutralized the homologous HAV strain, HM-175, in a radioimmunofocus assay and two of the four MAbs
neutralized a heterologous simian HAV strain, AGM-27. From these data, we conclude that the MAbs must recognize at least
three epitopes on the HAV capsid. Furthermore, competition assays performed with neutralizing murine MAbs suggested that
three of the chimpanzee MAbs recognized epitopes on the HAV capsid which have not been defined previously. © 2002 Elsevier
Science
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Hepatitis A virus (HAV), a positive-sense RNA virus, is
a member of the family Picornaviridae. It is the causative
agent of hepatitis A and is transmitted via the fecal–oral
route, mainly through contaminated water supplies and
food sources. Humoral immunity provides an effective
defense against hepatitis A. Prior to the availability of the
current inactivated virus vaccines, pooled human im-
mune globulin preparations were routinely used to pro-
tect individuals traveling to areas of the world where
hepatitis A is endemic (Hollinger and Ticehurst, 1996).
Unlike the neutralization of other members of the Picor-
naviridae, such as poliovirus and human rhinovirus, very
little is understood about antibody-mediated neutraliza-
tion of HAV. This is despite the fact that some strains of
the virus grow in cell culture, albeit much less efficiently
than do other picornaviruses.
The hepatitis A virion is an icosahedron composed of
pentamers of three structural proteins, VP1, VP2, and
VP3. A fourth structural protein found in other picornavi-
ruses, VP4, is truncated in HAV and has not been iden-
tified in virions. Epitopes recognized by neutralizing an-
tibodies on the HAV capsid are dependent on the con-
formation of the antigen. Very few neutralizing antibodies
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127have been generated to expressed antigens or subunit
proteins. Therefore, the mapping of these epitopes has
been achieved by a laborious process of generating
antibody-escape mutants by serially passaging the virus
in cell culture in the presence of neutralizing mouse
MAbs. The majority of the mutations selected thus far
appear to form an immunodominant site comprising
amino acids from both VP1 and VP3. A relatively small
number of mutations accounts for escape of these mu-
tants from neutralization by most of the neutralizing mu-
rine MAbs available. For example, HM-175 viruses with
single amino acid mutations in either VP3 at position 70
or 74, or VP1 at positions 102, 117, 176, or 221 escaped
neutralization by 21 of 22 mouse MAbs tested (Ping and
Lemon, 1992).
Bacteriophage particles displaying libraries of anti-
body fragments on their surface have provided a power-
ful tool for the generation of human monoclonal antibod-
ies (MAbs) to a variety of infectious agents (e.g., human
immunodeficiency virus type 1 (Ditzel et al., 1997), hep-
atitis C virus (Plaisant et al., 1997), Ebola virus (Ma-
ruyama et al., 1999)), as well as to cancer markers (e.g.,
melanoma (Pereira et al., 1997), adenocarcinoma (Hen-
derikx et al., 1998), and ovarian carcinoma (Figini et al.,
1998)). MAbs produced from such human antibody gene
libraries have the potential to serve directly as immune
prophylactic or therapeutic reagents against infectious
agents.
Chimpanzees are susceptible to infection with HAV
and can produce antibodies which neutralize the virus.
Chimpanzee immunoglobulins are virtually identical to
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human antibodies for clinical applications. We have used
a bone marrow derived cDNA library of antibody genes
displayed as Fab fragments on the surface of bacterio-
phage particles to isolate chimpanzee monoclonal anti-
bodies to the HAV capsid. These MAbs may be useful in
further defining the properties of neutralizing antibodies
that prevent hepatitis A as well as for clinical applica-
tions.
The combinatorial antibody library described in this
article was generated from a chimpanzee that had been
infected with the five recognized hepatitis-causing vi-
ruses, hepatitis A, B, C, D, and E viruses. The chimpan-
zee was seropositive for antibodies to all five viruses.
Previously, we used this antibody library to isolate MAbs
to the hepatitis E virus capsid protein (Schofield et al.,
2000). In this second analysis of the library, we have
used inactivated whole HAV particles as the panning
antigen to isolate four MAbs to the HAV capsid. Their
characterization, in terms of neutralization activities and
epitope topographies, are described.
RESULTS
Isolation of HAV-specific Fabs and sequence analysis
After three rounds of panning on formalin-inactivated
HAV particles coated to ELISA wells, 300 clones were
analyzed for HAV-specificity by ELISA. Twenty-four
clones were determined to be HAV-specific.
The restriction enzyme BstNI cuts frequently in the
human 1-heavy chain (Marks et al., 1991). This enzyme
was used to screen for different heavy-chain sequences
among the Fab clones. Several different digestion pat-
terns were observed (data not shown), suggesting that
more than one heavy chain sequence was present.
Sequence analysis was performed on 13 of the 24
clones. From these 13 clones, four unique 1-heavy
chains were identified. They were represented by clones
HAV#4, HAV#5, HAV#6, and HAV#14 (Fig. 1).
FIG. 1. A comparison of the amino acid sequenceWe attempted to determine the specific germ-line ori-
gin of the four clones by conducting a sequence similar-ity search of all the known human immunoglobulin
genes. The findings are summarized in Table 1.
Neutralization of HAV strain HM-175
The ability of the four MAbs, as Fab fragments, to
neutralize HAV in vitro was determined by radioimmuno-
focus assay (RIFA). The HAV strain used in the neutral-
ization assay, HM-175, was the same as the panning
antigen. The virus was mixed individually with each of
the four purified Fabs and incubated at room tempera-
ture for 2 h, and then serial 10-fold dilutions were inoc-
ulated onto confluent 11-1 cell monolayers. The mono-
layers were overlaid with medium containing agarose
and incubated at 34.5°C. After 10 days, the cells were
fixed and stained and the foci of infected cells were
detected by autoradiography. All four Fabs neutralized
the HM-175 strain of HAV (Fig. 2).
Neutralization of the simian HAV strain AGM-27
The AGM-27 strain is one of the most divergent HAV
strains identified thus far (Tsarev et al., 1991). In the
capsid proteins there are 28 amino acid changes com-
pared to the human strain HM-175 (1 amino acid change
in VP4, 6 amino acid changes in VP2, 7 amino acid
g1-heavy chains of the four HAV-specific MAbs.
TABLE 1
Classification of Chimpanzee g1-Chains of the Four HAV-Specific
MAbs, Based on Nucleotide Sequence Homology with Human Immu-
noglobulin Germ Line Genes
MAb
V H
family
V H
segment
D
segment
J H
segment
HAV#4 VH1 DP-25a D1-7b JH3b
HAV#5 VH5 DP-73a D4-11b JH6c
HAV#6 VH4 DP-78c D1-1b JH6c
HAV#14 VH5 DP-73 ND JH6c
a Tomlinson et al., 1992.
b Corbett et al., 1997.
c V-BASE database.
ND, not determined due to lack of identifiable homologue.
Fabs H
eutraliz
129HAV NEUTRALIZATION BY CHIMPANZEE MAbschanges in VP3, and 14 amino acid changes in VP1).
These amino acid changes include one of the two mu-
tations identified in VP3 and two of the four amino acid
mutations identified in VP1 as being involved in virus
escape from neutralizing mouse MAbs (Ping et al., 1988;
Ping and Lemon, 1992; Stapleton and Lemon, 1987).
The ability of the four Fabs to neutralize AGM-27 was
determined by RIFA. Each of the four Fabs was incubated
with virus as above, and the mixtures were serially di-
luted prior to inoculation onto 11-1 cells. After 14 days
incubation at 34.5°C, the cells were fixed and the RIFA
was performed. Examples of the RIFA coverslips are
shown in Fig. 3. Four well-characterized mouse MAbs
were used as controls. Mouse MAbs K2-4F2, K3-2F2,
and B5B3 did not neutralize the AGM-27 strain, whereas
mouse MAb K3-4C8 did neutralize the AGM-27 strain as
previously reported by Tsarev et al. (1991). Of the chim-
panzee Fabs, HAV#4 and HAV#6 neutralized the AGM-27
strain but HAV#5 and HAV#14 did not. Furthermore,
HAV#4 and HAV#6 bound to viral antigen in 11-1 cells
infected with AGM-27 as assayed by immunofluores-
cence microscopy. However, neither HAV#5 nor HAV#14
bound to antigen in this assay (data not shown).
Neutralization of an HM-175 VP3-070 mutant
FIG. 2. Assay of neutralization of HAV strain HM-175. Chimpanzee
whereas an irrelevant Fab, HBV#8 did not. Murine MAb K3-2F2 is a nNeutralization escape mutants generated in the pres-
ence of the mouse MAb K2-4F2 usually result in anamino acid change of Asp70 3 Ala70 in the VP3 capsid
protein (Nainan et al., 1992; Ping et al., 1988; Ping and
Lemon, 1992). This mutation is also present in the VP3
protein of the AGM-27 strain. Since HAV#5 and HAV#14
did not neutralize the AGM-27 strain, we tested for neu-
tralization of an HM-175 variant that had the VP3 Asp703
Ala70 mutation but otherwise was identical to the HM-175
strain (J. Graff, personal communication). The neutraliza-
tion assays were performed as described above. Each of
the four chimpanzee Fabs neutralized the HM-175 VP3-
070 mutant (Fig. 4). The control murine MAb K2-4F2 did
not.
Epitope mapping with Fabs
Indirect competition assays were performed to deter-
mine whether the four Fabs recognized similar or over-
lapping epitopes on the HAV capsid (Table 2). Unlabeled
HAV#4, HAV#5, and HAV#14 blocked the binding of bio-
tinylated HAV#4, HAV#5, and HAV#14 by .60%. There-
fore, these three Fabs recognize the same or overlapping
epitopes on the HAV capsid. Unlabeled HAV#6 did not
significantly block the binding of the other three biotin-
ylated Fabs and vice versa. Therefore, HAV#6 recognized
an epitope on the HAV capsid distinct from that recog-
nized by any of the other three Fabs. Indirect competition
AV#4, HAV#5, HAV#6, HAV#14 neutralized the HM-175 strain of HAV,
ation-positive control (see text).assays were also performed with the four Fabs and three
well-characterized mouse MAbs (Table 2). The binding of
mpanze
M-27, m
130 SCHOFIELD ET AL.MAbs K3-2F2 and K2-4F2 was inhibited approximately
50–60% by each of the four Fabs. Binding of MAb K3-4C8
to HM-175-coated wells was inhibited $84% by HAV#4,
FIG. 3. Assay of neutralization of the simian HAV strain AGM-27. Chi
Fabs HAV#5 and HAV#14 did not. Mouse MAb K3-4C8 neutralized AGFIG. 4. Assay of neutralization of HAV strain HM-175 carrying the VP3 As
HAV#14 neutralized this mutant virus. Murine MAb K2-4F2 is a neutralizationHAV#5, and HAV#14. This suggested that these three
Fabs and mouse MAb K3-4C8 recognized either the
same epitope or an overlapping epitope. HAV#6 inhibited
e Fabs HAV#4 and HAV#6 neutralized AGM-27; however, chimpanzee
ouse MAbs K2-4F2, K3-2F2, and B5B3 did not neutralize AGM-27.p70 3 Ala70 mutation. Chimpanzee Fabs HAV#4, HAV#5, HAV#6, and
-negative control (see text).
ibody b
131HAV NEUTRALIZATION BY CHIMPANZEE MAbsK3-4C8 binding by 61%, suggesting that the two corre-
sponding epitopes overlap to some extent or are at least
spatially close together on the HAV capsid.
The competition assays performed in this study were
subject to a number of variables which made quantitative
cutoff values for competing and noncompeting antibody
pairs very difficult to specify. For example, detection of
biotinylated Fab bound to HM-175-coated ELISA wells
was much more sensitive than detection of unlabeled
antibodies with secondary antispecies antibodies conju-
gated with alkaline phosphatase. Other factors such as
differences in antibody affinities for both primary and
secondary antibodies were unknowns which compli-
cated the data further. Therefore, within the context of
each assay we described antibodies as “competing”
when .60% inhibition of binding was observed, i.e., the
two epitopes recognized were likely to be the same or to
overlap extensively (Table 2; summarized in Table 3).
However, an antibody described as “noncompeting” did
not necessarily mean that there was no competition
between an antibody pair, rather that there was less
extensive overlap between two epitopes.
T
Indirect Competition Assay Data Using Fabs HAV#4, HAV#5, H
Fabs and Mouse MAbs
1st MAb HAV#4 HAV#5 HAV#6
HAV#4 85a 86 35
HAV#5 87 89 53
HAV#6 (6)b 28 92
HAV#14 65 61 22
a Percentage inhibition of antibody binding to HM-175-coated wells.
b Number in parentheses indicates percentage enhancement of ant
T
Summary of Neutralization Assay Data and Epitope Mapping
and Mouse MAbs K2-4F
Antibody
Neutralization
HM-175 VP3-070 AGM-27
HAV#4 Yes Yes Yes
HAV#5 Yes Yes No
HAV#14 Yes Yes No
HAV#6 Yes Yes Yes
K2-4F2 NDc No No
K3-4C8 ND ND Yes
K3-2F2 Yes ND No
B5B3 ND ND No
a “Yes” is defined as .60% inhibition of binding to HM-175-coated E
b Competition assays among the four chimpanzee MAbs were perforand the mouse MAbs were performed with whole IgG molecules.
c ND, not determined.Epitope mapping with IgGs
Indirect competition assays were also performed be-
tween the chimpanzee MAbs as whole IgG molecules
and the mouse MAbs K3-2F2, K3-4C8, K2-4F2 (MacGre-
gor et al., 1983), and mouse MAb B5B3 (Biogenesis).
Whole IgGs were tested to overcome any differences in
antibody affinity that may have arisen from comparing
monovalent chimpanzee Fab fragments and bivalent
mouse IgG molecules. This protocol would also exclude
differences in steric hindrance due to molecular size
disparities between Fab and IgG molecules. Here the
assay was performed in reverse with the mouse MAbs
used to block the binding of the four chimpanzee IgG
MAbs. Mouse MAb K3-4C8 reduced the binding of
HAV#4, HAV#5, and HAV#14 IgG to around 20–40% of the
respective controls. Mouse MAbs K3-2F2, K2-4F2, and
B5B3 could only reduce binding of HAV#4, HAV#5, and
HAV#14 IgG to a maximum of 60%, compared to the
respective controls. An example is shown in Fig. 5. All
four mouse MAbs had little effect upon the binding of
HAV#6 IgG to HM-175-coated wells. HAV#6 IgG binding
and HAV#14 to Block the Binding of Biotinylated Chimpanzee
2, K3-2F2, and K3-4C8
MAb (biotinylated)
HAV#14 K3-2F2 K3-4C8 K2-4F2
94 50 97 52
94 64 97 63
(10) 48 61 48
81 51 84 49
inding to HM-175-coated wells.
for Chimpanzee MAbs HAV#4, HAV#5, HAV#6, and HAV#14,
2F2, K3-4C8, and B5B3
Epitope mappinga
HAV#4b HAV#5 HAV#14 HAV#6
Yes Yes Yes No
Yes Yes Yes No
Yes Yes Yes No
No No No Yes
No No No No
Yes Yes Yes No
No No No No
No No No No
ells for each antibody pair.
ith Fab fragments; competition assays between the chimpanzee MAbsABLE 2
AV#6,
K2-4F
2ndABLE 3
Data
2, K3-
LISA w
med w
132 SCHOFIELD ET AL.was reduced maximally to 60% of the control. These data
confirmed those obtained with the Fab fragments.
Cell receptor-blocking assay
Indirect competition assays were performed to deter-
mine whether these chimpanzee MAbs could inhibit vi-
rus–cell receptor interaction. When HM-175-coated wells
were incubated with the Fabs prior to the addition of the
soluble HAV cell receptor, HAVCR1 (derived from African
green monkey kidney cells (Silberstein et al., 2001)),
blocking of receptor binding to the HM-175 was not
observed (Fig. 6). In the reciprocal assay, HAVCR1 was
unable to inhibit the binding of any of the Fabs to HM-
175-coated wells (data not shown). The above was also
repeated with the chimpanzee MAbs as whole IgGs.
Again inhibition was not observed with either IgG or
HAVCR1 as the blocking agent (data not shown).
DISCUSSION
The cDNA library used to isolate the antibodies to HAV
is a potential repository for antibodies to all five recog-
nized human hepatitis viruses, HAV, HBV, HCV, HDV, and
HEV, since the donor chimpanzee had been experimen-
tally infected with each of the hepatitis viruses. In the first
analysis of the library, two neutralizing MAbs directed to
the putative HEV capsid protein were identified
(Schofield et al., 2000). In this second analysis of the
library, four MAbs directed to the HAV capsid were iden-
tified. The 1-heavy chains of the HAV MAbs were most
closely related, at the nucleotide level, to 1-heavy chains
from the human VH1, VH4, and VH5 gene families; such
chimpanzee-derived immunoglobulin sequences differ
from human-derived sequences no more than geneti-
cally distinct human sequences differ from each other.
Furthermore, human-derived immunoglobulins exhibit
the same half-life in chimpanzees as they do in humans,
suggesting that human antibodies are recognized as self
and not foreign antigens.
Competition assays suggested the MAbs recognized
FIG. 5. Indirect competition assay between HAV#4 IgG, and the
mouse MAbs, K3-2F2 (), K3-4C8 (n ), K2-4F2 (F), and B5B3 (}). The
greatest inhibition of HAV#4 IgG binding was with K3-4C8 preincubated
with HAV-coated ELISA wells.more than one epitope on the HAV capsid since the three
MAbs competed strongly with each other (HAV#4,HAV#5, and HAV#14) for binding but the fourth (HAV#6)
competed poorly. All four MAbs neutralized the HAV
strain HM-175, the same strain used as the panning
antigen. Two of the four MAbs also neutralized the di-
vergent AGM-27 strain and two did not. This, taken with
the competition assay data, indicated that there were at
least three different epitopes recognized by the four
MAbs. Of the three MAbs which competed with each
other, HAV#4 recognized a unique epitope since the
MAb neutralized both HM-175 and AGM-27, whereas a
different epitope was recognized by HAV#5 and HAV#14
since these two MAbs neutralized HM-175 but not
AGM-27; the noncompeting MAb, HAV#6, recognized a
third epitope (this MAb neutralized both HM-175 and
AGM-27).
Competition assays were performed with the four
chimpanzee MAbs, as both Fabs and whole IgG mole-
cules, and the mouse MAbs K3-2F2, K3-4C8, K2-4F2, and
B5B3. We have attempted to draw a topographical map
of the antibody epitopes recognized by the murine and
chimpanzee MAbs based on our competition data and
other published data (Ping et al., 1988; Ping and Lemon,
1992; Stapleton and Lemon, 1987) (Fig. 7). In accordance
with previously published data, the epitopes are closely
spaced; the majority of the chimpanzee MAb epitopes
are shown closely overlapping with that of the murine
MAb K3-4C8. The competition and neutralization data
(summarized in Table 3) suggested that MAb K3-4C8 and
HAV#4 either recognized the same epitope or two
epitopes which overlap extensively. In contrast, the data
overall suggested that the other three chimpanzee MAbs
(HAV#5, HAV#6, HAV#14) recognize epitopes different
from those recognized by the majority of neutralizing
murine MAbs. Since escape mutants implicated VP3-
070, VP1-102, and VP1-221 as critical for neutralization by
the murine MAbs, it can be presumed that these amino
acids are not components of the epitopes recognized by
the chimpanzee MAbs. Indeed, VP3-070 has been exper-
imentally excluded since all four chimpanzee MAbs neu-
tralized the HM-175 VP3-070 mutant and two MAbs,
HAV#4 and HAV#6, neutralized the AGM-27 virus which
also has the VP3-070 mutation. The fact that AGM-27
FIG. 6. Virus-cell receptor blocking assay, with a range of dilutions of
blocking Fabs HAV#4 (}), HAV#5 (n ), HAV#6 (), and HAV#14 (F), and
a constant amount of soluble receptor HAVCR1. None of the four Fabs
was able to block HAVCR1 binding to HAV-coated ELISA wells.
133HAV NEUTRALIZATION BY CHIMPANZEE MAbswas not neutralized by HAV#5 or HAV#14 means that one
or more of the amino acids differentiating the capsid
proteins of the HM-175 and AGM-27 strains must be
critical for epitope recognition by these antibodies: un-
fortunately this narrows the possibilities only down to 27
amino acids after the VP3-070 amino acid is excluded.
HAV#6 neutralized both the HM-175 VP3-070 mutant
virus and the simian HAV strain AGM-27. Therefore,
HAV#6 appears to recognize a novel epitope on the HAV
capsid that is not defined by any of the amino acid
differences between HM-175 and AGM-27. In future work
we hope to determine if any amino acid mutations allow
escape from neutralization by the four chimpanzee
MAbs. However, it is possible that no amino acid muta-
tions will be identified if a mutation in a particular epitope
renders the virus nonviable.
It is conceivable that the two sets of antibodies (mu-
rine and chimpanzee) are directed to distinct epitopes on
the HAV capsid because of differences in antigen pro-
cessing by the mouse and chimpanzee antigen-present-
ing cells as has been suggested for poliovirus (Uhlig and
Dernick, 1988). However, competition studies with mu-
rine anti-HAV MAbs and anti-HAV positive human sera
suggest that this is not the case for HAV (Ping and
Lemon, 1992). Our results may also reflect differences in
the affinities for the HAV capsid of these two sets of
MAbs (murine and chimpanzee). If one antibody in the
pair had a significantly higher affinity for the HAV capsid
than did the other, then the lower affinity antibody may
not have been able to compete successfully for binding
to the capsid even if it recognized the same epitope. Due
to the large amount of highly purified virus needed to
FIG. 7. The predicted topography of the epitopes recognized by four
chimpanzee MAbs HAV#4, HAV#5, HAV#6, and HAV#14 within the
context of the topography of epitopes characterized by mouse MAbs
K3-4C8, K2-4F2, K3-2F2, and B5B3 (Ping et al., 1988; Ping and Lemon,
1992; Stapleton and Lemon, 1987). Overlap between any two circles
indicates .50% inhibition of binding. HAV#4, HAV#5, and HAV#14
epitopes are represented by a single circle; however, HAV#4 splits into
a different group based upon its ability to neutralize the simian HAV
strain, AGM-27.determine antibody affinities, we have been unable to
address this question.Recently it has been observed that antibodies to some
picornaviruses are able to neutralize virus infectivity by
inhibiting the virus–cell receptor interaction (Smith et al.,
1996). However, little is known about the mechanisms by
which antibodies neutralize hepatitis A virus. We exam-
ined whether our neutralizing MAbs were able to inhibit
the binding of the soluble simian cell HAV receptor,
recently isolated by Kaplan et al. (1996), to HM-175-
coated wells. In indirect competition assays between the
soluble receptor and each of the chimpanzee MAbs (as
IgG or Fab), neither was able to inhibit the other from
binding to HM-175-coated wells. Therefore, it seems
unlikely that these antibodies neutralize virus infectivity
by inhibiting virus attachment to cells via this receptor.
The actual mechanism(s) by which these antibodies neu-
tralize the virus remains undetermined. However, since
the antibodies neutralized as Fab fragments, it is clear
that bivalent binding is not necessary for neutralization.
Convalescent human anti-HAV, in the form of normal
immune globulin, has been used for decades as a pre-
exposure and postexposure immunoprophylactic agent
against hepatitis A. In recent years its use has dimin-
ished because of its unavailability and because licensed
hepatitis A vaccines have replaced it for most preexpo-
sure applications. However, vaccination requires a min-
imum of 2 weeks to achieve protection and postexposure
prophylaxis therefore continues to be a legitimate appli-
cation for immune globulin. In addition, there are other
potential uses for such globulin: fulminant hepatitis A
has been reported to account for up to 10–20% of liver
transplants in children in some countries (Ciocca, 2000)
and to be more common in adults who have coexisting
liver disease (Lefilliatre and Villeneuve, 2000; O’Grady,
2000; Vento, 2000). Also, although normally self-limiting,
HAV infection can cause persistent or relapsing hepati-
tis, especially in those who are immunosuppressed; re-
current hepatitis A has been reported following liver
transplantation for fulminant disease (Gane et al., 1995).
This has prompted the suggestion that HAV-specific im-
mune globulin be given at the time of transplantation for
HAV-induced acute liver failure to prevent such recur-
rences (Gane et al., 1995). Thus, there continue to be
potential clinical applications for a broadly reactive and
potent hepatitis A immune globulin. It will be interesting
to determine the efficacy of immunoglobulin derived from
the MAbs described herein for preventing and possibly
treating hepatitis A.
In conclusion, we have characterized four chimpanzee
MAbs to the HAV capsid, which were generated from a
library of antibody genes amplified by PCR with human
heavy- and light-chain gene-specific primers. Our com-
petition data with previously well-characterized murine
MAbs seem to be in accordance with the earlier studies
that suggest there is a single immunodominant antigen
site on the HAV capsid. Our MAbs competed with one of
the murine MAbs that were used to define this site.
134 SCHOFIELD ET AL.However, at least three of our chimpanzee MAbs appear
to be directed to epitopes as yet undefined by previous
studies. Thus one might speculate that although there
are no gross differences in antigen presentation be-
tween the murine and primate systems there may be
subtle differences in how antigens are presented to the
two immune systems.
MATERIALS AND METHODS
Animals
Chimpanzee 1441 had been experimentally infected
with the HAV strain, HM-175. Bone marrow was aspi-
rated from the iliac crest of this animal 6 years postin-
fection. Three weeks prior to the bone marrow aspira-
tion, the animal was boosted with a single dose of the
inactivated HAV vaccine, HAVRIX (SmithKline Beecham),
which contains the HM-175 capsid. The animal was
maintained in an approved facility under conditions that
met or exceeded all requirements for animal use.
Construction of 1/k antibody phage library
The library construction was described in detail in
Schofield et al. (2000).
Panning and ELISA reagents
Fabs were detected by enzyme-linked immunosorbant
assays (ELISA) with goat anti-human IgG (H1L)-specific
antibody (Pierce). This was coated on EIA/RIA A/2 plates
(Costar) overnight at 4°C at a dilution of 1:1000, in 50 mM
sodium carbonate buffer (pH 9.6). In all panning experi-
ments and other ELISAs, formalin-inactivated HAV parti-
cles (HM-175 strain; Viral Antigens Inc.) were diluted 1:2
in 50 mM sodium carbonate buffer (pH 9.6) and coated
on microtiter wells as above.
Library screening
Screening of the combinatorial library was carried out
as described previously (Barbas et al., 1991; Schofield et
al., 2000; Williamson et al., 1993). Phages were selected
by three rounds of panning on HM-175-coated ELISA
wells. After amplification of the selected library, the
phagemid DNA was extracted and modified by restric-
tion enzyme digestion to allow soluble Fab expression in
Escherichia coli. Single colonies were picked; Fab pro-
duction was induced as described previously (Glamann
et al., 1998), and the bacterial supernatants were tested
by ELISA for reactivity with HAV virions and for the
presence of Fab.
Fab production, purification, and biotinylation
Bacterial culture and Fab fragment purification were
carried out as described by Glamann et al. (1998). Protein
concentrations were determined both by dye bindingassay (Bio-Rad) and by A280 nm (using the extinction
coefficient of 1.4 optical density units equivalent to 1.0 mg
ml21). The Fab purity was determined by polyacrylamide
gel electrophoresis followed by colloidal Coomassie
blue staining (Sigma). The purified Fabs were diluted in
sodium bicarbonate buffer (pH 9.0), and biotinylated at
4°C as per the manufacturer’s protocol (Pierce). After
biotinylation, the Fabs were dialyzed against phosphate-
buffered saline (PBS) (pH 7.4) overnight at 4°C and con-
centrated in Centricon-30 concentrators (Amicon) as re-
quired.
ELISA analysis of Fab specificity
HAV was coated on ELISA microtiter plates at a 1:2
dilution and nonspecific proteins (thyroglobulin, ly-
sozyme, glyceraldehyde-3-phosphate, chicken albumen,
and cytochrome C (Sigma)) were coated at 10.0 mg ml21.
ELISAs were performed as detailed previously (Schofield
et al., 2000).
Restriction digestion analysis and nucleic acid
sequence analysis of HAV-specific Fab clones
For BstN1 (New England Biologicals) fingerprinting, 1
mg of plasmid DNA was digested with 1 U of enzyme
overnight at 60°C. The restriction digests were analyzed
on a 3% agarose gel. Nucleic acid sequencing was
performed with the ABI PRISM Dye Terminator Cycle
Sequencing Ready Reaction Kit with Ampli-Taq DNA
Polymerase (Perkin–Elmer) and the sequencing primers
HC1 and HC4 for the heavy-chain and LC1 and LC4 for
the k-chain (Glamann et al., 1998). Sequences were
analyzed with the GeneWorks (Oxford Molecular Group)
software package. Sequence similarity searches were
performed with the V-BASE program, which is a compi-
lation of all the available human variable segment Ig
germ line sequences (Cook and Tomlinson, 1995).
Radioimmunofocus assay
A modified radioimmunofocus assay was performed
as described by Raychaudhuri et al. (1998). Briefly, chlo-
roform-extracted HAV was mixed with antibody diluted in
10% BSA/PBS and incubated for 2 h at room temperature.
Log10 dilutions of the virus–antibody mixtures were inoc-
ulated onto confluent monolayers of fetal rhesus kidney
(subclone 11-1) cells grown on 25-mm-diameter Ther-
monox plastic coverslips (fixed to the bottom of each
well) for 1 h at 34.5°C in a CO2 incubator. The infected
cells were then overlaid with 0.5% agarose–MEM sup-
plemented with glutamine, gentamycin, and 2% FCS and
incubated for 10–14 days at 34.5°C. The cell monolayers
were fixed with acetone, air dried, and stored at 220°C
until stained. HAV foci were reacted with a 1:500 dilution
of chimpanzee 1442 antisera for 30 min at 34.5°C. The
cells were washed three times in PBS–glycine and then
incubated with 125I-labeled sheep anti-human IgG F(ab9)2
135HAV NEUTRALIZATION BY CHIMPANZEE MAbsfragment (1.0 mCi/ml; Amersham) for 1 h at 34.5°C. After
four washes, the coverslips were air dried and exposed
to X-ray film (Kodak) at 270°C.
Epitope mapping by indirect competition ELISA
The competing MAbs were titrated on HM-175-coated
wells to determine the dilution that gave an OD reading
of approximately 1.0 at A405 nm and did not saturate the
antigen coated to the plate. For the competition assay,
threefold dilutions of unlabeled MAbs were incubated in
HM-175-coated wells for 1 h at 37°C and then washed
four times with PBS-Tween 20. A single dilution of the
competing MAb (biotinylated Fab, whole IgG, or mouse
IgG) was incubated in all wells for 1 h at 37°C. After four
washes with PBS–Tween 20, the binding of the compet-
itor MAb was detected with either streptavidin–alkaline
phosphatase (Pierce), anti-human IgG (Fc-specific) alka-
line phosphatase-conjugated antibody (Sigma), or anti-
mouse IgG (H1L chain-specific) alkaline phosphatase-
conjugated antibody (Pierce).
Conversion of Fab to whole IgG molecules and
expression in COS-7 cells
The heavy- and light-chain genes of the MAbs were
subcloned into pFab-CMV (a kind gift from Dr. Pietro
Sanna (Sanna et al., 1999)) using the same restriction
enzyme sites used to clone the heavy- and light-chain
genes into the phage display vector, pComb3H. After
confirming the sequence of each clone, whole IgGs were
obtained from tissue culture supernatants 5 days post-
transfection of confluent COS-7 cells in T-75 flasks
(Costar). Transfection of the plasmid DNAs was per-
formed with Superfect transfection reagent (Qiagen) ac-
cording to the manufacturer’s instructions.
Cell receptor-blocking assay
A range of dilutions of the soluble simian cell receptor
for HAV, HAVCR1 (kindly provided by Dr. Gerardo Kaplan
(Silberstein et al., 2001)), was incubated in HM-175-
coated wells for 1 h at 37°C. After washing, a constant
amount of MAb was added to the wells and incubated for
1 h at 37°C. The bound antibody was detected with an
anti-human IgG Fab-specific alkaline phosphatase-la-
beled secondary antibody (1:5000). The optical density
was measured at 405 nm with a reference wavelength of
650 nm. Reciprocal assays were also performed with
dilutions of the anti-HAV antibodies and constant
amounts of HAVCR1. HAVCR1 was generated as a fusion
protein with the human IgG Fc region, and binding was
detected with an anti-human IgG (Fc-specific) alkaline
phosphatase-labeled secondary antibody (1:5000).
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